Management of side effects associated with sunitinib therapy for patients with renal cell carcinoma
| Autor: | Anita Schwandt, Laura S. Wood, Robert Dreicer, Brian I. Rini |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2009 |
| Předmět: |
Oncology
renal cell carcinoma medicine.medical_specialty medicine.drug_class sunitinib Review Pharmacology urologic and male genital diseases lcsh:RC254-282 Tyrosine-kinase inhibitor chemistry.chemical_compound tyrosine kinase inhibitor Renal cell carcinoma Internal medicine medicine Pharmacology (medical) Progression-free survival business.industry Sunitinib Cancer medicine.disease lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens Vascular endothelial growth factor side effects chemistry Anticipation (genetics) business Intracellular medicine.drug |
| Zdroj: | OncoTargets and Therapy, Vol 2009, Iss default, Pp 51-61 (2009) OncoTargets and therapy |
| ISSN: | 1178-6930 |
| Popis: | Anita Schwandt1,Laura S Wood1, Brian Rini1,2, Robert Dreicer1,21Department of Solid Tumor Oncology; 2Taussig Cancer Institute and the Glickman Urological and Kidney Institute; Cleveland Clinic, Cleveland OH, USAAbstract: Advances in the understanding of the biology of renal cell carcinoma have led to recent approval of several new agents including drugs that target vascular endothelial growth factor. Sunitinib is an oral tyrosine kinase inhibitor which interferes with multiple intracellular tumorogenic pathways, and has demonstrated impressive antitumor activity in phase II and subsequently improvement in progression free survival in phase III renal cancer trials. We review the unique side effects of sunitinib therapy with emphasis on establishing effective patient education for anticipation and early management of therapy-related side effects.Keywords: sunitinib, renal cell carcinoma, side effects, tyrosine kinase inhibitor |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|